We also found that Rac/Cdcd42 inhibitors may promote an anti-tumor microenvironment by inhibiting the secretion of the pro-inflammatory cytokine IL-6, which is mostly produced by tumor- associated macrophages. This evidence concerns the gene IL6 and neoplasm.